Clinical Trial Update: ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating ARC1905 in combination with Lucentis for neovascular age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• ARC1905 (ARC1905)
• Lucentis (ranibizumab)

Snippet

Sponsor: Ophthotech Corporation | Conditions: Neovascular Age-Related Macular Degeneration | Phase 1 | Status: COMPLETED